Ductal Carcinoma In Situ is the most common form of non-invasive breast cancer accounting for about 1 out of every 5 new breast cancers. About 15-30% of DCIS breast cancers will develop a tumor within 10 years of initial breast cancer treatment and about half of these will be invasive tumors. Being able to predict which DCIS breast cancers will develop into invasive tumors would enhance breast cancer treatments.
Fortunatelynew breast cancer research suggests that cellular markers in DCIS tissue samples might be able to predict future tumor formation. This new study suggests that over-expression of cellular markers (called p16 and COX-) involved in stress activation can predict better or worse breast cancer outcomes under certain conditions. In the absence of cell growththese markers predict a low chance of tumor recurrence. Contrastinglyin the presence of cell growththese markers predict a high chance of breast cancer recurrence. Additionallythese markers were reported to identify a subtype of DCIS breast cancer that is similar to basal-like invasive breast cancera form of breast cancer that is aggresive and has a short relapse time.
This is exciting research that opens new doors to breast cancer treatment. The ability to predict future breast cancer development from current breast cancer characteristics will hopefully lead to newmore targeted treatments to prevent the formation of these future breast tumors. This could lead to improved quality of life and better overall breast cancer survival.
In addition to preventing breast cancer recurrenceit is also important to reduce the risk of initial breast cancer formation. Read my book Fight Now: Eat & Live Proactively Against Breast Cancer at www.fightBCnow.com to learn what you can do to reduce your personal breast cancer risk.